Form 4: Celularity Director Peter Diamandis Increases Equity Stake

Celularity Inc. Director Peter Diamandis reported the acquisition of 125,000 restricted stock units and 156,250 stock options, increasing his beneficial ownership in the company.

Summary

• Peter Diamandis, a Director of Celularity Inc. (CELU), reported changes in his beneficial ownership.
• He acquired 125,000 Restricted Stock Units (RSUs) under the Celularity Inc. 2021 Equity Incentive Plan.
• Each RSU represents a right to receive one share of Class A common stock, granted at a price of $0.00.
• He also acquired 156,250 stock options under the 2021 Plan, with an exercise price of $1.2 per share.
• The RSUs and stock options will vest on the earlier of the one-year anniversary of the grant date (December 29, 2025) or the next annual stockholder meeting, subject to continuous service.
• Following these transactions, Mr. Diamandis beneficially owns 373,765 shares of Class A Common Stock (including the 125,000 RSUs) and 518,774 stock options.

Sentiment

Score: 6

Explanation: The filing reports an insider increasing their equity stake through grants, which is generally viewed as a positive signal of confidence in the company's future, though it is a routine compensation event.

Positives

• Director Peter Diamandis increased his equity stake in Celularity Inc. through the acquisition of 125,000 Restricted Stock Units and 156,250 stock options.
• The grants align the director's interests with those of shareholders, as the value of these awards is tied to the company's stock performance.
• The acquisition of equity by an insider can be interpreted as a sign of confidence in the company's future prospects.

Negatives

• No direct negatives are presented in this Form 4 filing, as it primarily reports a transaction.

Risks

• The vesting of the 125,000 Restricted Stock Units and 156,250 stock options is subject to Peter Diamandis's continuous service with Celularity Inc. through the vesting date.

Future Outlook

The vesting schedule for the granted RSUs and stock options indicates a future commitment from Director Peter Diamandis to Celularity Inc., with vesting contingent on his continuous service through the one-year anniversary of the grant date or the next annual stockholder meeting.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity transaction and does not provide information to analyze broader industry trends or competitor actions. However, equity grants are a common mechanism in the biotechnology and healthcare sectors to incentivize and retain key personnel.

Comparison to Industry Standards

• This filing reports a standard equity grant to a director under an existing equity incentive plan, which is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology. Specific comparable companies or projects are not detailed in this transaction report.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant to a director, Peter Diamandis, which is a common form of compensation for related parties (insiders).

Stakeholder Impact

• Shareholders: May view the director's increased equity stake as a positive signal of confidence in the company's future performance.
• Employees: No direct impact mentioned, but such grants are part of broader compensation strategies.
• Management: The grants incentivize the director's continued service and alignment with company goals.

Next Steps

• Vesting of 125,000 Restricted Stock Units on the earlier of December 29, 2026, or the next annual stockholder meeting.
• Vesting of 156,250 Stock Options on the earlier of December 29, 2026, or the next annual stockholder meeting.

Key Dates

Keywords

Celularity, CELU, Peter Diamandis, Form 4, insider transaction, restricted stock units, RSUs, stock options, equity incentive plan, director, beneficial ownership